Search results for "cervical"

showing 10 items of 511 documents

Frequency of a positive family history of colorectal cancer in general practice: a cross-sectional study.

2016

BACKGROUND Evidence on the frequency of a positive family history of colorectal cancer (CRC) among individuals aged <55 years is lacking. General practice setting might be well suited for the identification of individuals in this above-average risk group. OBJECTIVE To determine the frequency of a reported positive family history of CRC among patients aged 40 to 54 years in a general practice setting. METHODS We conducted a cross-sectional study in 21 general practices in Germany. Patients aged 40 to 54 years were identified by means of the practice software and interviewed by health care assistants using a standardized four-item questionnaire. Outcome was occurrence of a positive family his…

OncologyAdultMalemedicine.medical_specialtyAdenomaCross-sectional studyColorectal cancerGeneral PracticeColonic PolypsUterine Cervical NeoplasmsNuclear Family03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineGermanymedicinePrevalenceHumans030212 general & internal medicineFirst-degree relativesFamily historyMedical History TakingOvarian NeoplasmsUrethral Neoplasmsbusiness.industryCancerMiddle Agedmedicine.diseasedigestive system diseasesConfidence intervalKidney NeoplasmsPedigreeCross-Sectional StudiesGeneral practice030211 gastroenterology & hepatologyFemaleFamily PracticebusinessColorectal NeoplasmsFamily practice
researchProduct

Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes--correlation with clinico-pathological parameters and…

2001

OBJECTIVE To assess whether the presence of human papilloma virus (HPV) DNA and/or several genotypes of HPV DNA in primary cervical cancer and cancer free pelvic lymph nodes are correlated with several clinicopathological parameters of well-defined prognostic significance and whether virological parameters are predictors of long-term survival in cancer patients. PATIENTS AND METHODS 223 cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the high sensitive polymerase chain reaction (PCR) method followed by …

OncologyAdultmedicine.medical_specialtyGenotypeUterine Cervical NeoplasmsAdenocarcinomaPolymerase Chain Reactionlaw.inventionCarcinoma AdenosquamouslawInternal medicineGenotypeMedicineHumansNeoplasm InvasivenessLymph nodePapillomaviridaePolymerase chain reactionAgedRetrospective StudiesCervical cancerAged 80 and overbusiness.industryPapillomavirus InfectionsObstetrics and GynecologyCancerMiddle Agedmedicine.diseasePrognosisPrimary tumorSurvival AnalysisKoilocyteTumor Virus Infectionsmedicine.anatomical_structureLymphatic MetastasisDNA ViralCarcinoma Squamous CellFemaleLymphLymph NodesbusinessFollow-Up StudiesZentralblatt fur Gynakologie
researchProduct

The presence of HPV DNA in cervical cancer: correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the De…

2001

The objective of this study was to assess whether the presence of human papillomavirus (HPV) DNA and/or several genotypes of HPV DNA in cervical cancer are correlated with several clinicopathologic parameters of well-defined prognostic significance and whether virologic parameters are predictors of long-term survival in cancer patients. Two hundred twenty three cases of cervical cancer patients included in this retrospective study underwent follow-up evaluation. Survival and cause of death were examined for 204 (91.4%) patients, with a mean follow-up time of 4.4 years. HPV DNA was detected using the highly sensitive polymerase chain reaction (PCR) method followed by HPV DNA sequencing for H…

OncologyAdultmedicine.medical_specialtyGenotypeUterine Cervical NeoplasmsAdenocarcinomaPolymerase Chain Reactionlaw.inventionCarcinoma AdenosquamouslawInternal medicineGenotypemedicineCarcinomaHumansPapillomaviridaePapillomaviridaeSurvival analysisPolymerase chain reactionAgedRetrospective StudiesGynecologyCervical cancerAged 80 and overbiologybusiness.industryPapillomavirus Infectionsvirus diseasesObstetrics and GynecologyCancerMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisSurvival Analysisfemale genital diseases and pregnancy complicationsTumor Virus InfectionsOncologyDNA ViralCarcinoma Squamous CellAdenocarcinomaFemalebusinessInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology.

2010

Objective To determine human papillomavirus (HPV) types among cervical smears using polymerase chain reaction (PCR) and to contribute to the knowledge of human papillomavirus genotype distribution and prevalence of oncogenic types in cervical lesions in Spain. Study Design Consensus PCR and direct sequencing of PCR products (DNA HPV typing) were used in a retrospective study to determinate the type or types of HPV on 974 cytology smears of women with abnormal cytology results. Results Of 974 smears, 79.8% were high-risk (H-R) HPVs, 19.7% low-risk (L-R) HPVs, 4.6% indeterminate-risk (I-R) HPVs, considering both single and multiple infections. Multiple infections were detected in 4.7% of the …

OncologyAdultmedicine.medical_specialtyHistologyGenotypeCost effectivenessPopulationPrevalenceUterine Cervical NeoplasmsAlphapapillomavirusCervical intraepithelial neoplasiaPolymerase Chain ReactionPathology and Forensic MedicineGene FrequencyCytologyInternal medicineGenotypemedicinePrevalenceHumansMass ScreeningeducationMass screeningRetrospective StudiesGynecologyVaginal Smearseducation.field_of_studyHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus Infectionsvirus diseasesGeneral Medicinemedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsSquamous intraepithelial lesionSpainDNA ViralFemalebusinessActa cytologica
researchProduct

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

2011

Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …

OncologyAdultmedicine.medical_specialtyInvasive cervical cancerGenotypeUterine Cervical NeoplasmsHPV vaccinesAdenocarcinomaAlphapapillomavirusInternal medicineGenotypemedicineHumansPapillomavirus VaccinesHuman papillomavirusGenotypingAgedGynecologyCervical cancerHuman papillomavirus 16HPV typesVaccinesHpv typesHuman papillomavirus 18business.industryHPV PositivePapillomavirus Infectionsvirus diseasesObstetrics and GynecologyTime trendsMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOncologySpainCervical cancerFemalebusiness
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Clinical outcome of recurrent locally advanced cervical cancer (LACC) submitted to primary multimodality therapies

2015

Abstract Objectives Recurrence of disease represents a clinical challenge in cervical cancer patients, especially when all available treatment modalities have been used in the primary setting. The aim of this study was to analyze the patterns of recurrence and their association with clinical outcome in locally advanced cervical cancer (LACC) patients submitted to primary chemoradiation (CTRT) followed by radical surgery (RS). Methods This study was conducted on 364 LACC patients treated with CTRT plus RS since January 1996 to July 2012. For each relapse, information on date of clinical/pathological recurrence, and pattern of disease presentation were retrieved. Post-relapse survival (PRS) w…

OncologyAdultmedicine.medical_specialtyUterine Cervical Neoplasmrecurrent cervical cancerPrognosimedicine.medical_treatmentUterine Cervical NeoplasmsDiseaseObstetrics and gynaecologyRetrospective StudieInternal medicinemedicineHumansRadical surgeryChemoradiation; Post-relapse survival; Prognosis; Radical hysterectomy; Recurrent cervical cancer; Adult; Chemoradiotherapy; Adjuvant; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence; Local; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical NeoplasmschemoradiationSurvival analysisNeoadjuvant therapyAdjuvantRetrospective StudiesSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIACervical cancerbusiness.industrypost-relapse survivalObstetrics and GynecologyRetrospective cohort studyChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseSurvival AnalysisNeoadjuvant TherapySurgeryLog-rank testTreatment OutcomeNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyLocalradical hysterectomyFemaleSurvival AnalysiprognosisNeoplasm Recurrence LocalbusinessHuman
researchProduct

Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers.

2005

Abstract Purpose: Glucose transporter-1 (GLUT-1), a target gene of hypoxia-inducible factor-1, has been considered a candidate endogenous marker of tumor hypoxia. Expression of GLUT-1 may also serve as an indicator for the induction of the transcriptional response to hypoxia, which has been linked to enhanced proliferation, resistance to therapy, and metastatic propagation of cancer cells. Overexpression of GLUT-1 has been shown to correlate with poor prognosis in several tumor entities, among them cancers of the uterine cervix. The validity of these hypotheses is investigated. Experimental Design: The expression of GLUT-1 was assessed in 80 biopsies of Eppendorf oxygenation measurement tra…

OncologyCancer Researchmedicine.medical_specialtyPathologyMonosaccharide Transport ProteinsUterine Cervical NeoplasmsBiologyInternal medicinemedicineHumansSurvival analysisNeoplasm StagingProportional Hazards ModelsCervical cancerGlucose Transporter Type 1Tumor hypoxiaProportional hazards modelGlucose transporterHypoxia (medical)Middle Agedmedicine.diseaseImmunohistochemistrySurvival AnalysisOxygenOncologyCancer cellMultivariate AnalysisImmunohistochemistryFemalemedicine.symptomClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Participation in cervical cancer screening in Germany.

2010

OncologyCervical cancerAdultmedicine.medical_specialtyEpidemiologybusiness.industryPublic Health Environmental and Occupational HealthUterine Cervical NeoplasmsMiddle AgedCervical cancer screeningmedicine.diseaseYoung AdultInternal medicineGermanymedicineHumansMass ScreeningFemalePatient ParticipationbusinessAgedPreventive medicine
researchProduct

116 Evaluation of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer: data from phase 1 and phase 2 studies

2021

Introduction/Background* The accelerated US Food and Drug Administration approval of pembrolizumab validated the efficacy of anti-PD-(L)1 therapy for patients with recurrent/metastatic cervical cancer; however, the objective response rate (ORR) with pembrolizumab was 14.3% in patients with PD-L1–expressing tumours. Human papillomavirus infection is implicated in >95% of cervical cancers and is linked to upregulation of TGF-β signalling. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (a TGF-β ‘trap’) fused to a human immunoglobulin G1 monoclonal antibody blocking PD-L1. We report pooled safety and efficacy in pati…

OncologyCervical cancermedicine.medical_specialtyBevacizumabbiologybusiness.industryHistologyPembrolizumabmedicine.diseaseImmune checkpointInternal medicinePD-L1Toxicitymedicinebiology.proteinbusinessProgressive diseasemedicine.drugCervical cancer
researchProduct